Immune Checkpoint Inhibitors Market is Anticipated to Cross US$ 25 Billion by 2022 Due to Increasing Prevalence of Cancer and Immune Diseases: Radiant Insights, Inc.

News provided by

Oct 10, 2018, 08:10 ET

SAN FRANCISCO, October 10, 2018 /PRNewswire/ --

The global Immune Checkpoint Inhibitors Market is likely to witness a higher CAGR in the forecast period. Oncology is a wide field with various diagnoses and applications. Increase in cancer cases and a gradual shift toward immunotherapies is likely to enhance the market conditions on a global level. Immunotherapy thus enables the body to fight on its own in the cancerous conditions. Immunity checkpoint offers a desired approach to the therapeutic antitumor immunity. It refers to the wider options of inhibitory pathways embedded into immune system that are vital for modulating the biological immune responses present in outer tissues to lessen the severity of collateral damage. The key drivers for the market development for immune checkpoint inhibitors include surge in cancer cases across the globe and demand for minimally invasive procedures. Rise in government support and favorable reimbursement is likely to drive the market growth in the forecast period. Government funding for research activities and development of effective drugs is likely to boost the market growth in the forecast period. Increasing investments by the pharmaceutical companies is expected to boost the market growth during the forecast period. Product segmentation for immune checkpoint inhibitors market includes PD-1, PD-L1 and CTLA-4. PD-1 segment is expected to account for a higher market share owing to rise in number of market entrants in the pharmaceutical sector. Application segment for immune checkpoint inhibitors market include renal cancer, lung cancer, bladder cancer, blood cancer, melanoma and Hodgkin lymphoma. Geographical segmentation for immune checkpoint inhibitors market includes North America, South America, Europe, Asia-Pacific, Middle East and Africa.

North American and European markets have been at the forefront due to enhances in the medical infrastructure and rise in cancer cases. Asia-Pacific regions are likely to grow at a significant CAGR due to increasing prevalence of cancer and immune diseases. Existence of pharmacy and manufacturing sector is likely to stimulate the regional market growth. Asia-Pacific regions are likely to gain a significant growth in the forecast period due to rise in research and development coupled with flexible norms and regulations for approval. The key players in the Immune Checkpoint Inhibitors Market include Novartis AG, AstraZeneca Plc, Merck & Co, Squibb, Roche Holdings AG, F.Hoffman-La Roche, Pfizer Inc, Bristol-Meyers and Incyte. Given the wealth of potential targets to overcome tumor-induced immune suppression, many novel active immunotherapies are in clinical development across a range of solid tumor types. The most advanced in development are checkpoint inhibitors. These checkpoint inhibitors have dramatically altered the natural history of hard-to-treat cancers by producing substantial clinical benefits for certain tumor types and patients. Some of these checkpoints are called PD-1, PD-L1, and CTLA-4 receptors. They work by activating the body's immune system against antigens expressed on tumor cells. Drugs that target these checkpoints hold great promise and have generated a tremendous interest in further developing and exploring these strategies across the oncology disease spectrum.

Access 60 page research report with TOC on "Immune Checkpoint Inhibitors Market" available with Radiant Insights, Inc. @ https://www.radiantinsights.com/research/global-immune-checkpoint-inhibitors-market-outlook-2022

According to the report "Global Immune Checkpoint Inhibitors Market Outlook 2022", the global immune checkpoint inhibitors market is anticipated to cross US$ 25 Billion by 2022. The report provides a detailed analysis of the global immune checkpoint inhibitors market. The report also provides the current and forecasted market for immune checkpoint inhibitors. Furthermore, the report provides insights about the major drivers and challenges, along with the latest trends and developments impacting the industry growth. In addition, the report also highlights various opportunities available for growth of the global immune checkpoint inhibitors market. Moreover, the report provides the sales of commercialized immune checkpoint inhibitors. The global immune checkpoint inhibitors market has been segmented on the basis of type of product into PD-1, PD-L1, and CTLA-4. According to the report, PD-1 segment was estimated to account for the largest share in 2016 due to entry of multiple pharmaceutical players in the PD-1 inhibitors market, increasing investments from various key pharmaceutical companies and active research with many pharmaceutical companies looking to launch their products. On the basis of type of cancer, the immune checkpoint inhibitors market is dominated by Lung Cancer & Melanoma applications with several companies and academic institutions focusing on novel treatment approaches, thus making the major contribution to the global immune checkpoint inhibitors market.

A major focus has been on the ongoing clinical trials for the development of innovative products. In this context, the report provides information about the immune checkpoint inhibitors programs at various stages of clinical development. In addition, the report highlights the strategic collaborations amongst the players for enhancing their market share. The later part of the report discusses some of the prominent players in the global immune checkpoint inhibitors market. A brief business overview of each player has been provided along with their product and pipeline portfolios and recent developments. Overall, immune checkpoint inhibitor is an important and rapidly emerging field. This report will prove as a complete source of knowledge and analysis for clients and potential investors.

Browse reports of similar category available with Radiant Insights, Inc.:

About Radiant Insights, Inc.:

At Radiant Insights, we work with the aim to reach the highest levels of customer satisfaction. Our representatives strive to understand diverse client requirements and cater to the same with the most innovative and functional solutions.

Contact:
Michelle Thoras.
Corporate Sales Specialist
Radiant Insights, Inc.
Phone: +1-415-349-0054
Toll Free: 1-888-928-9744
Email: [email protected]

Web: https://www.radiantinsights.com

SOURCE Radiant Insights, Inc.